RMR Capital Management’s AbbVie ABBV Stock Holding History

RMR Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.32M	Hold	9,212	–	–	1.6%	19
2026 Q1	$2M	Hold	9,212	–	–	1.45%	21
2025 Q4	$2.1M	Hold	9,212	–	–	1.51%	19
2025 Q3	$2.13M	Hold	9,212	–	–	1.49%	18
2025 Q2	$1.71M	Hold	9,212	–	–	1.22%	23
2025 Q1	$1.93M	Hold	9,212	–	–	1.37%	20
2024 Q4	$1.64M	Hold	9,212	–	–	1.21%	25
2024 Q3	$1.82M	Hold	9,212	–	–	1.49%	20
2024 Q2	$1.58M	Hold	9,212	–	–	1.44%	20
2024 Q1	$1.68M	Hold	9,212	–	–	1.54%	21
2023 Q4	$1.43M	Buy	+9,212	New	+$1.34M	1.63%	21

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

RMR Capital Management's ABBV Position: Q2 2026 in Review

RMR Capital Management held its AbbVie (ABBV) position steady in Q2 2026 at 9,212 shares worth $2.32M. The position accounts for 1.6% of the portfolio, ranked #19.

RMR Capital Management first reported a position in ABBV in Q4 2023 and has held it in 11 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

RMR Capital Management held 9,212 shares of AbbVie worth $2.32M as of Q2 2026.
RMR Capital Management left its AbbVie share count unchanged in Q2 2026.
AbbVie made up 1.6% of RMR Capital Management's portfolio in Q2 2026, its #19 holding.
RMR Capital Management first reported a position in AbbVie in Q4 2023 and has held it in 11 quarters since.
4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on RMR Capital Management's 13F filing for Q2 2026, filed 27 Jul 2026.